Current investors


Let’s work together

At Macrolide Pharmaceuticals, we are eager to collaborate with academic institutions and other companies who are interested in macrolide development, and anti-bacterials broadly. We believe that collaborative alliances are the most effective way to develop new medicines. If you would like to discuss working together, we’d be delighted to speak with you.

Learn about our science

Our platform, published in Nature in 2016, allows for the synthesis of macrolides not limited by the structure of the natural product erythromycin, but from basic chemical building blocks. This enables us to rationally design Gram-negative activity into our compounds and to anticipate and overcome resistance mechanisms.
Our science